T2D: Dapagliflozin consistently reduces CV and kidney disease risk irrespective of background therapy

Key clinical point: Dapagliflozin consistently reduced the risk for cardiovascular (CV) death or hospitalization for heart failure (HHF) and kidney disease progression irrespective of the background CV medication in patients with type 2 diabetes (T2D) with a consistent safety profile.

Major finding: Dapagliflozin vs placebo led to a consistent reduction in the composite of CV death/HHF, HHF alone, and kidney-specific outcomes irrespective of the background CV medications (P_interaction > .05), with patients not using diuretics showing better kidney specific outcomes (P_interaction  =  .003). Serious adverse events were not significantly different between the dapagliflozin and placebo groups.

Study details: Findings are from a prespecified secondary analysis of the DECLARE-TIMI 58 trial including 17,160 patients with T2D and either atherosclerotic disease or multiple CV risk factors.

Disclosures: The DECLAR-TIMI 58 trial was supported by AstraZeneca. One author reported being an employee and shareholder of AstraZeneca. Some authors reported receiving research funding or support, honoraria, personal fees, or consulting or speaker fees, or serving as advisory board members for various sources, including AstraZeneca.

Source: Oyama K et al. Efficacy and safety of dapagliflozin according to background use of cardiovascular medications in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022 (Jul 20). Doi: 10.1001/jamacardio.2022.2006

Key clinical point: Dapagliflozin consistently reduced the risk for cardiovascular (CV) death or hospitalization for heart failure (HHF) and kidney disease progression irrespective of the background CV medication in patients with type 2 diabetes (T2D) with a consistent safety profile.

Major finding: Dapagliflozin vs placebo led to a consistent reduction in the composite of CV death/HHF, HHF alone, and kidney-specific outcomes irrespective of the background CV medications (P_interaction > .05), with patients not using diuretics showing better kidney specific outcomes (P_interaction  =  .003). Serious adverse events were not significantly different between the dapagliflozin and placebo groups.

Study details: Findings are from a prespecified secondary analysis of the DECLARE-TIMI 58 trial including 17,160 patients with T2D and either atherosclerotic disease or multiple CV risk factors.

Disclosures: The DECLAR-TIMI 58 trial was supported by AstraZeneca. One author reported being an employee and shareholder of AstraZeneca. Some authors reported receiving research funding or support, honoraria, personal fees, or consulting or speaker fees, or serving as advisory board members for various sources, including AstraZeneca.

Source: Oyama K et al. Efficacy and safety of dapagliflozin according to background use of cardiovascular medications in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022 (Jul 20). Doi: 10.1001/jamacardio.2022.2006

Key clinical point: Dapagliflozin consistently reduced the risk for cardiovascular (CV) death or hospitalization for heart failure (HHF) and kidney disease progression irrespective of the background CV medication in patients with type 2 diabetes (T2D) with a consistent safety profile.

Major finding: Dapagliflozin vs placebo led to a consistent reduction in the composite of CV death/HHF, HHF alone, and kidney-specific outcomes irrespective of the background CV medications (P_interaction > .05), with patients not using diuretics showing better kidney specific outcomes (P_interaction  =  .003). Serious adverse events were not significantly different between the dapagliflozin and placebo groups.

Study details: Findings are from a prespecified secondary analysis of the DECLARE-TIMI 58 trial including 17,160 patients with T2D and either atherosclerotic disease or multiple CV risk factors.

Disclosures: The DECLAR-TIMI 58 trial was supported by AstraZeneca. One author reported being an employee and shareholder of AstraZeneca. Some authors reported receiving research funding or support, honoraria, personal fees, or consulting or speaker fees, or serving as advisory board members for various sources, including AstraZeneca.

Source: Oyama K et al. Efficacy and safety of dapagliflozin according to background use of cardiovascular medications in patients with type 2 diabetes: A prespecified secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022 (Jul 20). Doi: 10.1001/jamacardio.2022.2006